著者

KURIMOTOTsukasa/ASAKANaomasa/MAEDAToshimatsu/IRIMURAKenji/MATSUURANaosuke

雑誌

岐阜藥科大學紀要 = The annual proceedings of Gifu College of Pharmacy

巻号頁・発行日

vol.49, pp.45-52, 2000-06-30

---

MET-88,an inhibitor of γ-butyrobetaine hydroxylase, can be characterized as a unique cardioprotective agent for the treatment of congestive heart failure (CHF) with an ability to regulate the activity of SR Ca^<2+>-ATPase. MET-88 protected the hypoxic and ischemic myocardium due to the modulation of myocardial metabolism and improved cardiac remodeling and hypertrophy as effectively as captopril. MET-88 also increased the failed Ca^<2+>-ATPase activity in the Sarcoplastic reticulum (SR), which increase might have resulted from ATP synthesis through glycolysis. These effects of MET-88 may be expected to improve mortality, prognosis, and exercise intolerance in CHF patients. In summary, MET-88 may be a useful drug for the treatment of CHF.